Iron citrate complex, process for its production, and its pharmaceutical |
| We claim: 1. An iron citrate micellar complex, which is a brown solid having the properties set out ... |
|
Specifically .beta.-.beta. cross-linked hemoglobins and method of preparation |
| The present invention provides a modified hemoglobin comprising hemoglobin which is cross-linked ... |
|
Apparatus for manufacturing granulated material |
| The invention proceeds from the consideration that it is not possible to reduce the width of the ... |
|
Substituted and bridged pyridines useful as calcium channel blockers |
| OF THE INVENTION The specific substituted and bridged pyridine compounds of this invention are ... |
|
Ace inhibitors in macular degeneration |
| OF THE INVENTION The novel method of treatment of senile macular degeneration of this invention ... |
|
Derivatives of 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonines and -1,4-benzoxazonines, processes for their production and their use as pharmaceuticals |
| We claim: 1. 2,3,4,5,6,7-Hexahydro-2,7-methano-1,5-benzoxazonine and -1,4-benzoxazonine compounds, ... |
|
Novel benzylalcohol derivatives and processes for preparing the same |
| What we claim is: 1. A compound of the formula: ##STR11## wherein R is a lower alkyl group having 1-... |
|
Method of use of bicycloheptane substituted prostaglandin analogs as cardiovascular agents |
| What is claimed is: 1. A method of inhibiting arachidonic acid-induced platelet aggregation and ... |
|
|
Derivatives of cis, endo-2-azabicyclo[5.3.0]decane-3-carboxylic acid, and their use for treating hypertension
| Details |
Inventors: Urbach, Hansjorg; Henning, Rainer; Teetz, Volker; Becker, Reinhard;
Assignee: Hoechst Aktiengesellschaft (DE)
Primary Examiner: Bond; Robert T.
Assistant Examiner: Springer; D. B.
Attorney, Agent or Firm: Finnegan, Henderson, Farabow, Garrett & Dunner
The invention relates to derivatives of cis,endo-2-azabicyclo[5.3.0]decane-3-carboxylic acid of the formula I ##STR1## in which R denotes hydrogen, alkyl, alkenyl or aralkyl, R.sup.1 denotes hydrogen, allyl, vinyl or a side chain of an optionally protected naturally occurring .alpha.-aminoacid, R.sup.2 denotes hydrogen, alkyl, alkenyl or aralkyl, Y denotes hydrogen or hydroxyl, Z denotes hydrogen, or Y and Z together denote oxygen, X denotes alkyl, alkenyl, cycloalkyl, aryl which can be substituted once, twice or three times by alkyl, alkoxy, hydroxyl, halogen, nitro, amino, alkylamino, dialkylamino or methylenedioxy, or denotes indol-3-yl, and their physiologically acceptable salts, a process for their preparation, agents containing them and their use. |
|
DETAILED DESCRIPTION We claim: 1. A compound of the formula I ##STR11## in which the hydrogen atoms on the bridgehead C atoms 1 and 5 have the cis-configuration relative to one another and the carboxyl group on C atom 3 is oriented endo to the bicyclic ring system and in which R denotes hydrogen, (C. sub. 1 -C. sub. 6)-alkyl, (C. sub. 2 -C. sub. 6)-alkenyl or (C. sub. 6 -C. sub. 12)-aryl-(C. sub. 1 -C. sub. 4)-alkyl, R. sup. 1 denotes hydrogen, allyl, vinyl or a side chain of an optionally protected, naturally occurring . alpha. -amino-acid R. sup. 1 CH(NH. sub. 2)--COOH, R. sup. 2 denotes hydrogen, (C. sub. 1 -C. sub. 6)-alkyl, (C. sub. 2 -C. sub. 6)-alkenyl or (C. sub. 6 -C. sub. 12)-aryl-(C. sub. 1 -C. sub. 4)-alkyl, Y denotes hydrogen or hydroxyl, Z denotes hydrogen or Y and Z together denote oxygen, X denotes (C. sub. 1 -C. sub. 6)-alkyl, (C. sub. 2 -C. sub. 6)-alkenyl, (C. sub. 5 -C. sub. 9)-cycloalkyl, (C. sub. 6 -C. sub. 12)-aryl which can be substituted once, twice or three times by at least one member selected from the group consisting of (C. sub. 1 -C. sub. 4)-alkyl, (C. sub. 1 -C. sub. 4)-alkoxy, hydroxyl, halogen, nitro, amino, (C. sub. 1 -C. sub. 4)-alkylamino, di-(C. sub. 1 -C. sub. 4)-alkylamino and methylenedioxy, or denotes indol-3-yl, and its physiologically acceptable salts. 2. A compound of the formula I as claimed in claim 1 in which R denotes hydrogen, R. sup. 1 denotes methyl, the optionally acylated side chain of lysine or the O-alkylated side chain of tyrosine, R. sup. 2 denotes hydrogen, methyl, ethyl, benzyl or tert. -butyl, X denotes phenyl or phenyl substituted once or twice with at least one member selected from the group consisting of fluorine and chlorine, Y denotes hydrogen or hydroxyl, Z denotes hydrogen or Y and Z together denote oxygen. 3. The compound according to claim 2 which is N-(1-S-Carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[5. 3. 0]de cane-3-S-carboxylic acid or its physioyogically acceptable salts. 4. The compound according to claim 2 which is N-(1-S-Carboxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[5
|
| Related patents |
|
|
Carboxyalkyl dipeptides and anti-hypertensive use thereof
We claim: 1. A compound represented by the formula ##STR12## and the pharmaceutically acceptable salts thereof, wherein R and R.sup.6 are the same or different and are ...
|
|
|
Optically active bicyclic imino-alpha-carboxylic esters
We claim: 1. A compound of the formulae Ia or Ib essentially free of its racemate, and salts of said compound, ##STR15## in which the two bridgehead hydrogen atoms have ...
|
|
|
5-HT.sub.3 receptor antagonists for treatment of cough and bronchoconstriction
I claim: 1. A method of treatment of cough and/or bronchoconstriction in mammals, which method comprises the administration to the mammal in need of such treatment, an ...
|
|
|
Therapeutic compositions with enhanced bioavailability
OF THE INVENTION This invention relates to compositions of a drug with a water soluble polymer which has been treated with a wetting sufficient amount of a wetting ...
|
|
|
Medicament adsorbates and their preparation
In particular, it has been found that a good tasting medicament adsorbate is produced from admixing about 1 to about 25% by weight of a medicament drug with about 8 to ...
|
|
|
Sustained release formulations
We claim: 1. In combination, a drug suitable for oral delivery and a delivery system for sustained release dosage of said drug comprising: (a) a core portion containing ...
|
|
|
Water dispersible gemfibrozil compositions
What is claimed is: 1. A water-dispersible formulation of gemfibrozil comprising finely divided particles of pure gemfibrozil uniformly coated with a mixture of a wax ...
|
|
|
Method and composition for enhancing the effect of indirect-acting sympathomimetic amines
OF SPECIFIC EMBODIMENTS In accordance with this invention, tyrosine or a tyrosine precursor such as phenylalanine is administered concomitnatly with an indirect-acting ...
|
|
|
1-azabicycloalkane derivatives, their preparation process and their use as medicaments
What is claimed is: 1. A compound of formula (I) ##STR5## in which n represents the number 1, R.sub.1 and R.sub.2, identical or different represent hydrogen or an ...
|
|
|
Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration
OF THE INVENTION The novel method of treatment of neurodegeneration of this invention comprises the administration to a patient in need of such treatment with an ...
|
|
|